India at a glance
- Population
- 1.46 billion 2025
- Life expectancy at birth
- 72.2 years, 2024
- People aged 65 and over
- 7.4 % of people, 2025
- Health spending per person
- 85 US$ per person, 2023
- Doctors
- 0.72 per 1,000 people, 2020
Updated
Reviewed by Chandani Patel
India In Vivo CAR-T Therapy Market Industry Trends and Forecast to 2034: Segmented by (Delivery, Indication, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034
Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.
Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.
$106.8 Mn total, 2026–2034
| Year | Market size | Change that year | Since 2025 |
|---|---|---|---|
| 2024 (estimate) | $1.5 Mn | — | — |
| 2025 (base) | $2.3 Mn | +$0.8 Mn | — |
| 2026 (forecast) | $3.6 Mn | +$1.2 Mn | +53.2% |
| 2027 (forecast) | $5.5 Mn | +$1.9 Mn | +134.7% |
| 2028 (forecast) | $8.4 Mn | +$2.9 Mn | +259.6% |
| 2029 (forecast) | $12.9 Mn | +$4.5 Mn | +450.9% |
| 2030 (forecast) | $19.8 Mn | +$6.9 Mn | +743.9% |
| 2031 (forecast) | $30.3 Mn | +$10.5 Mn | +1,192.9% |
| 2032 (forecast) | $46.5 Mn | +$16.1 Mn | +1,880.7% |
| 2033 (forecast) | $71.2 Mn | +$24.7 Mn | +2,934.4% |
| 2034 (forecast) | $109.1 Mn | +$37.9 Mn | +4,548.7% |
Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.
| Market size, 2025 | $2.3 Mn placeholder estimate |
|---|---|
| Forecast, 2034 | $109.1 Mn placeholder estimate |
| Growth (CAGR), 2025–2034 | 53.2% placeholder estimate |
| Years | 2024 historical · 2025 base year · 2026–2034 forecast |
| Segments | Delivery, indication and end user (see all) |
| Key players | Capstan Therapeutics (AbbVie), Umoja Biopharma, Interius BioTherapeutics, Kelonia Therapeutics, EsoBiotec (AstraZeneca) (see all) |
| Regulator in India | CDSCOSource: Central Drugs Standard Control Organisation. Checked 14 Nov 2026. |
| Formats | PDF, PPTX, XLSX |
Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.
In vivo CAR-T therapy delivers instructions straight into the body so a patient's own T cells become cancer fighters, without lab manufacturing.
Key segments of the in Vivo CAR-T Therapy market include delivery (Lentiviral Vectors, Lipid Nanoparticles and Targeted Viral Vectors) and indication (Blood Cancers, Autoimmune Diseases and Solid Tumors).
Approvals of the first curative gene and cell therapies, strong investment in biotech, better manufacturing and growing evidence in rare and blood diseases are driving the in Vivo CAR-T Therapy market.
Allogeneic (off-the-shelf) products, in-vivo delivery and use in common diseases open large growth for the in Vivo CAR-T Therapy market.
Very high prices, complex manufacturing, limited treatment centres and uncertain long-term safety hold back the in Vivo CAR-T Therapy market. Payers are still working out how to pay for one-time cures.
The in Vivo CAR-T Therapy market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.
New drugs and clinical trials need approval from the Central Drugs Standard Control Organisation (CDSCO), headed by the Drugs Controller General of India.[1] Ayushman Bharat PM-JAY gives eligible families hospital cover of up to ₹5 lakh a year.[2]
[1] Central Drugs Standard Control Organisation. Checked 14 Nov 2026.
[2] National Health Authority (PM-JAY). Checked 14 Nov 2026.
Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for in Vivo CAR-T Therapy. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in India.
What doctors and scientists are doing in In Vivo CAR-T Therapy right now, from free public sources.
Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, World Bank. Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.
[1] World Bank Open Data, Health spending per person (US$ per person). Retrieved 22 Nov 2026.
[2] World Bank Open Data, Doctors (per 1,000 people). Retrieved 21 Nov 2026.
[3] World Bank Open Data, People aged 65 and over (% of people). Retrieved 22 Nov 2026.
From our blog
India · 2 shared keywords
India · 1 shared keyword
India · 1 shared keyword
India · 1 shared keyword
India · 1 shared keyword
India · 1 shared keyword
Digital Health · India
Healthcare Services · India
Healthcare Services · India
Healthcare Services · India
Public Health · India
Medical Devices · India